Home > Boards > US Listed > Biotechs >

Aytu BioScience Inc. (AYTU)

Add AYTU Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/17/2018 11:39:54 AM - Followers: 16 - Board type: Free - Posts Today: 0

Ridiculous Market Cap of $16 M / Cash $11.8 M / 4 Marketed Products one of them called Natesto (hypogonadism) targeting $2 BILLION Market which has the potential to be the next market leader (please read below for more infos) Shares Out only 4.22 M . This low float stock should be valued at minimum $120-150 Million (~$30-35 per share ) right now for their marketed products .GL

Market Cap : $16 Million
Cash $11.8 Million
Price $4

Shares Out 4.22 Million


Fact Sheet

Marketed Products:

•Natesto–testosterone nasal gel indicated for hypogonadism ($2 billion market in the U.S., 13 million men diagnosed with hypogonadism (low testosterone)

•MiOXSYS–in vitro device for male infertility ($825 million International market ,30 million men impacted in U.S.)

•Fiera–pre-intimacy device to increase sexual desire and arousal in women (53 million women in the U.S. with sexual concerns)

•ProstaScint–imaging agent for prostate cancer

Don't you guys think that Aytu BioSciences Natesto, FDA approved, nasal TRT is far superior to Lipocines Tlando?

Aytu BioScience (AYTU) Stock: Why This Thing Can Grow Legs!

The Doors To Massive Potential Have Swung Wide Open

As if there already wasn't massive potential surrounding NATESTO, the flood gates may open soon as the competition has largely been cleared off of the playing field. That happened relatively recently when Acrux and Eli Lilly ended their relationship surrounding the testosterone product known as Axiron, a TRT applied under the arm.

It all started back in 2010 when Acrux and Eli Lilly entered into a license agreement surrounding Axiron. As a result of the deal, there would be $335 million plus potential royalties up for grabs. However, early this month, in fact on September 6th, it was announced that both companies have reached an agreement to terminate the license agreement.

While this may not seem like a big deal at first glance, it's massive. You see, Axiron was one of the only competing drugs that was marketed on a large scale. However, for this marketing to take place, it had to happen with the help of Eli Lilly. Since the relationship has been split, the marketing is no longer in place. As a result, AYTU has an open playing field with NATESTO, giving it the opportunity to tackle the market in a big way.

NATESTO Is Black Box Free

While there are many advantages that we see in NATESTO over other testosterone replacement therapies, there's one key advantage that really strikes us. That is the fact that the product is the only TRT (Testosterone Replacement Therapy) currently on the market that's not only effective, but comes with no black box warnings.

For those of you who don't know, black box warnings are among the strictest warnings that the FDA imposes on labeling of prescription drugs. These warnings are only used when there is reasonable evidence of an association of a serious hazard with the drug in question. While other TRTs on the market have various black box warnings associated with the risk of a man transferring testosterone gel to his female partner or child, NATESTO is black box warning free; making it one of the safest, if not the safest option for testosterone replacement.

The Bottom Line

The bottom line here is that AYTU has a tremendous opportunity and through this opportunity, poses a potentially incredible opportunity for investors themselves. Looking at NATESTO, it's clear that not only is this drug the safest option, it is likely to become the first option. With the sales force nearing the ability to hit the ground running and an incredible management team behind them, I believe that 2018 will be the year for AYTU; and we haven't even touched on Fiera or Mioxys yet.... those are topics for another day!

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AYTU News: Current Report Filing (8-k) 01/17/2018 09:06:52 AM
AYTU News: OTC Markets Group Announces Quarterly Index Performance and Rebalancing 01/16/2018 07:00:00 AM
AYTU News: Amended Statement of Ownership (sc 13g/a) 01/08/2018 09:50:23 AM
AYTU News: Statement of Changes in Beneficial Ownership (4) 01/03/2018 05:51:35 PM
AYTU News: Aytu BioScience to Present at Biotech Showcase 2018 Investor Conference 01/02/2018 08:05:00 AM
#151   Aytu BioScience Gets A Double Bonus From TLANDO® fatcat2 01/17/18 11:39:53 AM
#150   SA article out on AYTU. Added more here. fatcat2 01/12/18 11:04:10 AM
#149   I say no. There is something inherently wrong FancyThatRightThere 12/19/17 06:20:49 PM
#148   Geez .. you jump everywhere .. aytu is zoomlik 12/19/17 02:29:50 PM
#147   There's a reason mgmt. hired Green as new CFO. fatcat2 12/19/17 01:29:54 PM
#146   So glad I didn't buy. It is 98% FancyThatRightThere 12/19/17 11:30:00 AM
#145   Well, this certainly answers a LOT right here! FancyThatRightThere 12/19/17 01:59:07 AM
#144   Now where I have AN ENORMOUS PROBLEM is FancyThatRightThere 12/19/17 01:39:17 AM
#143   You're forgetting also that by then they should FancyThatRightThere 12/19/17 12:27:06 AM
#142   $900k was for Natesto which is highest growth zoomlik 12/18/17 11:31:50 PM
#141   First off, let's get #'s right. Last Q FancyThatRightThere 12/18/17 11:00:39 PM
#140   Please project your rev for Q ending dec zoomlik 12/18/17 08:29:49 PM
#139   That's the dumbest thing I ever heard. 35% FancyThatRightThere 12/18/17 08:23:06 PM
#138   Aytu BioScience Announces Appointment of David Green as fatcat2 12/18/17 11:28:12 AM
#137   Natesto rev last quarter was $900,000 .. expect zoomlik 12/15/17 11:29:18 PM
#136   This one crossed my scans today at work FancyThatRightThere 12/15/17 08:28:09 PM
#135   Think about it .. They had $7M left end zoomlik 12/15/17 07:19:51 PM
#134   They have enough till Middle of fiscal 2019 fatcat2 12/15/17 04:43:18 PM
#133   Reason I sold is they need to raise zoomlik 12/15/17 04:32:11 PM
#132   I sold at $2.75 with little profit zoomlik 12/15/17 04:31:07 PM
#131   What a crazy ride! Someone bought 200K shares fatcat2 12/15/17 04:09:08 PM
#130   Neusta is a hit .. we will see zoomlik 12/15/17 01:18:03 PM
#129   So Are you're a believer like me, or fatcat2 12/15/17 01:01:04 PM
#128   I expect pump by company .. some good news zoomlik 12/15/17 12:49:15 PM
#127   No .. lol zoomlik 12/15/17 12:48:36 PM
#126   You got your pump. Did you sell? fatcat2 12/15/17 12:14:12 PM
#125   I bought a few days ago zoomlik 12/15/17 11:38:44 AM
#124 fatcat2 12/15/17 11:10:20 AM
#123   Did you buy this week? fatcat2 12/15/17 11:08:49 AM
#122   I am expecting to see a big pump zoomlik 12/15/17 10:00:56 AM
#121   These articles were written by an individual who fatcat2 12/14/17 10:31:55 PM
#120   This is a good article .. but be zoomlik 12/14/17 07:28:18 PM
#119 fatcat2 12/14/17 06:09:25 PM
#118   What is the impact of Axiron being dropped zoomlik 12/14/17 05:07:23 PM
#117   They need cash to become profitable and also zoomlik 12/14/17 03:45:10 PM
#116   You took the words right out of my fatcat2 12/14/17 03:34:39 PM
#115   Per my math , company still needs $15M zoomlik 12/14/17 02:53:57 PM
#114   Who knows .. Aytu can become a billion zoomlik 12/14/17 01:35:34 PM
#113   Question for aytu is ... what price they zoomlik 12/14/17 01:11:02 PM
#112   Interstitial mngr .. they also have a 10M zoomlik 12/13/17 07:42:54 PM
#111   Looking at filings, split adjusted for 20 to zoomlik 12/13/17 07:11:32 PM
#110   I don't think there's any. They moved to fatcat2 12/13/17 04:31:43 PM
#109   " AYTU management guided investors that they believe fatcat2 12/13/17 04:05:22 PM
#108   Any analyst following these guys? zoomlik 12/13/17 04:00:45 PM
#107 fatcat2 12/13/17 03:40:12 PM
#106   The nasal TRT is huge though in a zoomlik 12/13/17 03:13:53 PM
#105   The sex thing has been selling for a zoomlik 12/13/17 02:24:40 PM
#104 fatcat2 12/13/17 01:59:38 PM
#103   Why do you like it? zoomlik 12/13/17 01:44:31 PM
#102   Since it was on OTC. I loaded up fatcat2 12/13/17 12:57:36 PM